Magda brings over a decade of research experience spanning oncology and inflammatory diseases. Before joining Epitopea, she served as Assay Development and Target Validation Lead at MiNK Therapeutics, where she established core cell-based assays for CAR, TCR and bi-specific engager discovery, led target identification efforts, and worked closely with CMC and translational teams to advance allogeneic iNKT therapies for cancer and ARDS.

She earned her PhD in Molecular Immunology from the University of Erlangen–Nuremberg (FAU), followed by an industrial postdoctoral fellowship at AstraZeneca investigating human tissue-resident regulatory T cells and their role in mucosal immunity.

Magda is committed to applying her expertise in immunology and drug discovery to advance translational research and bring forward therapies that enable patients to live fully beyond cancer.